Core Insights - Daxor Corporation will showcase its advanced blood volume analysis technology at the 45th International Society for Heart and Lung Transplantation Annual Meeting, which will take place from April 27-30, 2025, in Boston, MA, attracting around 3,500 specialists in heart and lung disease treatment [1][2] Company Overview - Daxor Corporation is recognized as the global leader in blood volume measurement technology, having developed the BVA-100® (Blood Volume Analyzer), the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition [3] - Over 65,000 tests have been conducted at leading hospitals in the U.S., significantly improving hospital performance metrics and reducing mortality and readmissions in heart failure and critical care [3] - The company is engaged in ongoing trials for heart failure treatment with support from the NIH and is also developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [3] Technology and Impact - Daxor's diagnostic technology provides 98% accurate data, facilitating personalized treatment for end-stage heart and lung patients, which enhances patient outcomes while lowering care duration and costs [2]

Core Insights - WellStar Health System's Advanced Heart Failure program has successfully reduced acute kidney injury rates following left ventricular assist device implantation through a blood volume analysis (BVA) approach [2] - Daxor Corporation will showcase its BVA technology at the MedAxiom CV Transforum Spring'25 Conference, emphasizing its role in improving patient outcomes [1][3] - BVA-guided care has demonstrated significant improvements in patient outcomes, including an 82% reduction in 30-day mortality, an 86% reduction in 1-year mortality, a 56% reduction in 30-day readmissions, and a 55% reduction in length of stay when implemented at admission [4] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, known for its BVA-100® (Blood Volume Analyzer), which is FDA-cleared for accurate quantification of blood volume status [5] - Over 65,000 BVA tests have been conducted in leading U.S. hospitals, contributing to improved performance metrics in various medical conditions, particularly in heart failure and critical care [5] - Daxor is involved in ongoing trials for heart failure treatment with support from the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [5] Industry Context - MedAxiom serves as a premier source for organizational performance solutions in the cardiovascular community, aiming to enhance outcomes, reduce costs, and improve patient and clinician experiences [6] - The MedAxiom CV Transforum conference brings together cardiovascular thought leaders and industry innovators to advance cardiovascular care [1][6]

Core Insights - Daxor Corporation announced new data indicating that blood volume analysis (BVA) can significantly improve survival rates for hospitalized heart failure patients when performed prior to discharge [1][2] Company Overview - Daxor Corporation (Nasdaq: DXR) is a leader in blood volume measurement technology, focusing on innovation in blood volume testing [3] - The company developed the BVA-100, the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition [3] - Over 65,000 tests have been conducted in leading U.S. hospitals, contributing to improved performance metrics and reduced mortality and readmissions in heart failure and critical care [3] Study Findings - A study involving 1,237 hospitalized heart failure patients showed that those identified as "euvolemic" through BVA had significantly better one-year survival rates compared to those who were hypervolemic [2][5] - The hazard ratio for death was found to be 2.61 times higher in the hypervolemic group compared to the euvolemic group, with a statistically significant p-value of 0.002 [5] - The correlation between blood volume status and survival outcomes remained significant even after adjusting for comorbidities, underscoring the clinical value of BVA [5] Implications for Heart Failure Management - The findings suggest that BVA can be a critical tool for optimizing treatment and ensuring proper decongestion before patient discharge [2] - The study supports the notion that precision volume management guided by BVA technology can save lives and improve outcomes for heart failure patients [2]

Advanced BVA System Designed for Faster, Simpler Bedside Testing Oak Ridge, TN, April 10, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), a leader in blood volume measurement technology, announces today the submission of its next-generation blood volume analyzer - Daxor BVA - to the Food and Drug Administration (FDA.), advancing its mission to optimize healthcare through precise fluid management. The new Daxor BVA device represents a significant leap forward in diagnostic technology, offering direc ...

BVA and Pressure Session Attracted 400+ Clinicians; Duke University Showcased Valuable New BVA Findings in Dedicated Poster Presentation Oak Ridge, TN, April 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces excellent visibility of Daxor’s technology at the premier global cardiology conference, the American College of Cardiology (ACC) 74th Annual Scientific Session and Expo held in Chicago from March 29-31st. New data presented ...

BVA and Pressure Session Attracted 400+ Clinicians; Duke University Showcased Valuable New BVA Findings in Dedicated Poster Presentation Oak Ridge, TN, April 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces excellent visibility of Daxor's technology at the premier global cardiology conference, the American College of Cardiology (ACC) 74th Annual Scientific Session and Expo held in Chicago from March 29-31st. New data presented f ...

Core Insights - Daxor Corporation is expanding its ezBVA Lab service into three regional healthcare facilities across the U.S., enhancing blood volume analysis capabilities and improving patient outcomes while reducing costs [2][3] - The ezBVA Lab provides comprehensive blood volume analysis results within 24 hours for both inpatient and outpatient settings, showcasing the efficiency and effectiveness of Daxor's technology [2][3] - Daxor's BVA technology has been integrated into various healthcare settings, including a prominent Midwest academic medical center and a leading cardiovascular institute in New Jersey, indicating its growing significance in modern healthcare [3][6] Company Overview - Daxor Corporation is recognized as the global leader in blood volume measurement technology, with its BVA-100® being the only FDA-cleared diagnostic blood test for quantifying blood volume status [4] - Over 65,000 tests have been performed at leading hospital centers across the U.S., significantly reducing mortality and readmissions in heart failure and critical care [4] - Daxor is involved in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [4]

Financial Data and Key Metrics Changes - As of December 31, 2024, Daxor's net assets increased to $36.79 million or $7.25 per share, up from $34.01 million or $7.08 per share at the end of 2023, reflecting a positive trend in net asset value [7] - For the year ended December 31, 2024, Daxor reported net dividend income of $0.10 million and net realized gains on investment securities of $1.36 million, while there was a net decrease in unrealized appreciation of $1.15 million due to the sale of positions [8] - The net increase in net assets from operations was $0.55 million, which included a non-cash stock-based compensation expense of $1.25 million [9] Business Line Data and Key Metrics Changes - Revenue in the operating company increased by 116.5% year-on-year from 2024 compared to 2023, indicating strong growth momentum [29] - The number of diagnostic kits sold rose by 60.1% year-on-year for 2023, following a growth of about 37% in the prior year [30] - The operating company achieved cash flow breakeven in the first quarter of 2025, excluding costs related to stock-based compensation, depreciation, and amortization [29] Market Data and Key Metrics Changes - Daxor signed 12 new accounts in 2024, including five that purchased analyzer systems, with three additional accounts signed in the first two months of 2025 [31] - The company received a $2.5 million contract from the U.S. Department of Defense, which will pay out monthly over a two-year duration [32] - Additional funding awards from the National Institutes of Health and other sources totaled more than $350,000 in the second half of 2024 [33] Company Strategy and Development Direction - Daxor aims to commercialize products for optimal patient care around blood volume management, focusing on improving outcomes for millions of patients [23] - The company is pursuing the development of next-generation blood volume analyzers, which are expected to significantly enhance speed, access, and accuracy in fluid management [44] - Daxor plans to bring manufacturing of diagnostic kits in-house, which is expected to increase margins and improve cash flow [46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, highlighting substantial progress in revenue growth, customer acquisition, and product utilization [22] - The management team emphasized the importance of real-world data generation and peer-reviewed publications to facilitate practice change in clinical settings [16] - The company anticipates that the transition to a more transparent reporting structure will positively impact its valuation and market potential [52] Other Important Information - Daxor is classified as a closed-end management company under the Investment Company Act of 1940, with plans to secure a designation as an operating company by the end of 2025 [51] - The company has developed strong relationships with various healthcare providers, expanding its market reach beyond traditional cardiology [15] Q&A Session Summary Question: Can you discuss the cash transfer to the operating company? - The company transferred $1.6 million to the operating company to cover capital expenditures, inventory build, and R&D, with the operating company achieving cash flow positivity in early 2025 [54][55] Question: What are the efforts to build the sales team? - The company is actively building its commercial teams through internal hires and potential distributor agreements, realizing substantial value from its unique technology [56] Question: Can you elaborate on the competitive landscape? - The competitive landscape is focused on indirect proxy measures, while Daxor has pioneered a more accurate method for directly measuring blood volume, providing a significant competitive advantage [58][59]

Core Insights - Daxor Corporation reported a strong financial performance for fiscal 2024, achieving a 116.5% increase in revenue compared to 2023, driven by robust demand for its diagnostic systems [4] - The company has successfully transitioned to cash-flow positive operations in Q1 of 2025, excluding non-cash expenses [4] - Daxor is focused on launching its next-generation blood volume analyzer, which is expected to enhance clinical workflows and open new market opportunities [2] Financial Highlights - The net asset value (NAV) per share increased to $7.25 for fiscal 2024 from $7.08 in 2023 [1] - Daxor signed 12 new accounts in 2024, resulting in a 60.1% growth in the number of diagnostic kits sold year-over-year [4] - The company secured a $2.5 million two-year contract from the Department of Defense, contributing to its commercial momentum [4] Operational Developments - Daxor's next-generation blood volume analyzer is set to be filed for FDA approval via the rapid 510(k) pathway, which will facilitate point-of-care blood volume measurements [2] - The first two months of 2025 saw record-breaking monthly kit revenue, indicating accelerating adoption of Daxor's products [4] - The company received over $350,000 in grants from NIH and Launch Tennessee to support ongoing research and development [4] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, with its BVA-100 being the only FDA-cleared diagnostic blood test for quantifying blood volume status [3] - The company has performed over 65,000 tests at leading hospital centers across the U.S., significantly improving patient outcomes in various medical conditions [3] - Daxor is engaged in ongoing trials for heart failure treatment with support from the NIH and is developing analyzers for combat casualty care with the U.S. Department of Defense [3]

Core Insights - Daxor Corporation will host an investor conference call on March 6, 2025, at 4:30 p.m. ET to review financial results and corporate developments [1][2] - The call will feature President and CEO Michael Feldschuh and CFO Robert Michel, followed by a Q&A session for investors [2] - Daxor is recognized as a leader in blood volume measurement technology, with its BVA-100™ being the only FDA-cleared diagnostic blood test for quantifying blood volume status [3] Company Overview - Daxor Corporation focuses on blood volume testing innovation and has performed over 65,000 tests at leading hospital centers in the U.S., significantly impacting patient outcomes in heart failure and critical care [3] - The company is involved in ongoing trials for heart failure treatment supported by the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [3] - Daxor's mission is to enhance healthcare through optimal fluid management via blood volume analysis, aiming for optimal blood volume for all patients [3]